Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy for liver metastases plus chemotherapy and serplulimab in ES-SCLC
ChiCTR2500105496Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in small cell lung cancer (SCLC), sponsored by Shandong First Medical University. Primary endpoint: Median progression-free survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500105496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105496.